FLT4 抗体 (Extracellular Domain)
Quick Overview for FLT4 抗体 (Extracellular Domain) (ABIN115161)
抗原
See all FLT4 抗体适用
宿主
克隆类型
标记
应用范围
克隆位点
-
-
抗原表位
- Extracellular Domain
-
特异性
- Detects Human VEGFR-3/FLT-4.
-
交叉反应 (详细)
- Species reactivity (tested):Human.
-
纯化方法
- Affinity Chromatography on Protein G.
-
免疫原
- Purified recombinant human Vascular Endothelial Growth Factor Receptor 3 (rh VEGFR-3/FLT-4) extracellular domain.
-
亚型
- IgG1
-
-
-
-
应用备注
-
ELISA: 0.5-1.5 μg/mL in direct ELISA, allows detection of 0.25-0.5 ng/well. Immunohistochemistry: 1-10 μg/mL. Western blot 0.5-1 μg/mL, detection limit is approximately 5 ng/lane under reducingconditions.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user. -
限制
- 仅限研究用
-
-
-
溶解方式
- Restore with sterile water to a concentration of 0.1-1.0 mg/mL
-
缓冲液
- PBS pH 7.4 without preservatives or stabilizers
-
储存液
- Without preservative
-
注意事项
- Avoid repeated freezing and thawing.
-
储存条件
- 4 °C/-20 °C
-
储存方法
- The lyophilized IgG is stable at 2-8 °C for one month and for one year from despatch when kept at -20 °C. When reconstituted in sterile water to a concentration of > 0.5 mg/ml the antibody is stable for six weeks at 2-8 °C or at -20 °C for longer. Aliquot to
-
有效期
- 12 months
-
-
-
: "Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 27, Issue 26, pp. e97-100, (2009) (PubMed).
-
: "Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 27, Issue 26, pp. e97-100, (2009) (PubMed).
-
- FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))
-
别名
- VEGFR-3 / Flt-4
-
背景
- VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk 1) and VEGFR-3 (FLT-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular and lymphatic endothelial cells and to the monocyte/macrophage lineage. These receptors play essential roles in vasculogenesis, hematopoiesis, angiogenesis and lymphangiogenesis. The VEGFR-3 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 24 aa residue signal peptide. Mature VEGFR-3 is composed of a 751 aa residue extracellular domain, a 22 aa residue transmembrane domain and a 482 aa residue cytoplasmic domain. Both VEGF-C and VEGF-D have been shown to bind and activate VEGF R3 (Flt-4). The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stage of development. It is important for lymphangiogenesis.Synonyms: FLT4, Tyrosine-protein kinase receptor FLT4, VEGF Receptor 3, VEGFR3, Vascular endothelial growth factor receptor 3
-
基因ID
- 2324
-
NCBI登录号
- NP_002011
-
UniProt
- P35916
-
途径
- RTK signaling, Signaling Events mediated by VEGFR1 and VEGFR2, VEGF Signaling
抗原
-